Kovitz Investment Group Partners LLC Sells 461 Shares of Hologic, Inc. (NASDAQ:HOLX)
Kovitz Investment Group Partners LLC decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,429 shares of the medical equipment provider’s stock after selling 461 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Hologic were worth $753,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Rational Advisors LLC lifted its position in Hologic by 45.8% in the 4th quarter. Rational Advisors LLC now owns 681 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 214 shares in the last quarter. CFM Wealth Partners LLC purchased a new position in shares of Hologic in the fourth quarter worth $39,000. Ancora Advisors LLC purchased a new position in shares of Hologic in the fourth quarter worth $39,000. Pacitti Group Inc. purchased a new position in shares of Hologic in the fourth quarter worth $52,000. Finally, CENTRAL TRUST Co lifted its holdings in shares of Hologic by 44.1% during the fourth quarter. CENTRAL TRUST Co now owns 1,013 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 95.15% of the company’s stock.
Shares of NASDAQ:HOLX opened at $32.26 on Thursday. The stock has a market capitalization of $8.28 billion, a price-to-earnings ratio of 35.07, a PEG ratio of 1.55 and a beta of 0.90. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.20 and a current ratio of 1.57. The stock’s 50-day simple moving average is $45.71 and its two-hundred day simple moving average is $49.47. Hologic, Inc. has a 52-week low of $26.49 and a 52-week high of $55.25.
HOLX has been the subject of several research analyst reports. Piper Sandler lifted their price objective on Hologic from to in a report on Thursday, January 30th. TheStreet upgraded shares of Hologic from a “c” rating to a “b+” rating in a research note on Wednesday, January 29th. BTIG Research restated a “buy” rating and set a $54.00 target price on shares of Hologic in a research note on Thursday, January 30th. Stifel Nicolaus raised their price target on shares of Hologic from $48.00 to $52.00 and gave the company a “hold” rating in a report on Friday, December 13th. Finally, Morgan Stanley lowered shares of Hologic from an “equal weight” rating to an “underweight” rating in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $55.53.
In related news, General Counsel John M. Griffin sold 19,624 shares of Hologic stock in a transaction on Monday, January 13th. The stock was sold at an average price of $52.86, for a total transaction of $1,037,324.64. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Karleen Marie Oberton sold 16,348 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $51.73, for a total value of $845,682.04. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
See Also: Market Perform
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.